Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance,

BofA lowered the firm’s price target on Arcus Biosciences (RCUS) to $17 from $22 and keeps a Neutral rating on the shares following Gilead’s

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the session, and are down 33% in the past 12 months.

Arcus Biosciences (NYSE:RCUS) shares dipped 4% after the company priced a stock offering to raise approximately $150 million. The offering consists of 13,636,364 shares of common stock issued at $11.00 per share Arcus intends to use the net proceeds from the offering to fund ongoing research and development activities,

Arcus Biosciences (RCUS) announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of